REPL
Price
$10.38
Change
+$0.63 (+6.46%)
Updated
Jun 6 closing price
Capitalization
800.16M
54 days until earnings call
SRPT
Price
$43.01
Change
+$3.80 (+9.69%)
Updated
Jun 6 closing price
Capitalization
4.23B
53 days until earnings call
Interact to see
Advertisement

REPL vs SRPT

Header iconREPL vs SRPT Comparison
Open Charts REPL vs SRPTBanner chart's image
Replimune Group
Price$10.38
Change+$0.63 (+6.46%)
Volume$1.93M
Capitalization800.16M
Sarepta Therapeutics
Price$43.01
Change+$3.80 (+9.69%)
Volume$4.85M
Capitalization4.23B
REPL vs SRPT Comparison Chart
Loading...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REPL vs. SRPT commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a StrongBuy and SRPT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (REPL: $10.38 vs. SRPT: $43.01)
Brand notoriety: REPL: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REPL: 156% vs. SRPT: 119%
Market capitalization -- REPL: $800.16M vs. SRPT: $4.23B
REPL [@Biotechnology] is valued at $800.16M. SRPT’s [@Biotechnology] market capitalization is $4.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REPL’s FA Score shows that 1 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • REPL’s FA Score: 1 green, 4 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, REPL is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REPL’s TA Score shows that 7 TA indicator(s) are bullish while SRPT’s TA Score has 5 bullish TA indicator(s).

  • REPL’s TA Score: 7 bullish, 3 bearish.
  • SRPT’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, REPL is a better buy in the short-term than SRPT.

Price Growth

REPL (@Biotechnology) experienced а +15.59% price change this week, while SRPT (@Biotechnology) price change was +14.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

REPL is expected to report earnings on Jul 31, 2025.

SRPT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRPT($4.23B) has a higher market cap than REPL($800M). REPL YTD gains are higher at: -14.286 vs. SRPT (-64.627). SRPT has higher annual earnings (EBITDA): -106.51M vs. REPL (-216.51M). REPL (537M) and SRPT (523M) have equal amount of cash in the bank . REPL has less debt than SRPT: REPL (76M) vs SRPT (1.34B). SRPT has higher revenues than REPL: SRPT (2.23B) vs REPL (0).
REPLSRPTREPL / SRPT
Capitalization800M4.23B19%
EBITDA-216.51M-106.51M203%
Gain YTD-14.286-64.62722%
P/E RatioN/A27.21-
Revenue02.23B-
Total Cash537M523M103%
Total Debt76M1.34B6%
FUNDAMENTALS RATINGS
REPL vs SRPT: Fundamental Ratings
REPL
SRPT
OUTLOOK RATING
1..100
223
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9592
PRICE GROWTH RATING
1..100
4395
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5029

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (28) in the Biotechnology industry is somewhat better than the same rating for SRPT (66). This means that REPL’s stock grew somewhat faster than SRPT’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SRPT (100). This means that REPL’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (92) in the Biotechnology industry is in the same range as REPL (95). This means that SRPT’s stock grew similarly to REPL’s over the last 12 months.

REPL's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for SRPT (95). This means that REPL’s stock grew somewhat faster than SRPT’s over the last 12 months.

REPL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SRPT (100). This means that REPL’s stock grew similarly to SRPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REPLSRPT
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
72%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 24 days ago
85%
Bearish Trend 15 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
74%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCGYX19.510.15
+0.77%
NYLI PineStone Global Equity Class C
OEICX88.08N/A
N/A
JPMorgan Equity Index C
MBCNX15.84N/A
N/A
MassMutual Blue Chip Growth R3
PCLCX18.15N/A
N/A
PACE Large Co Growth Equity P
PPQPX7.68N/A
N/A
Principal MidCap Growth III R5

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with ELVAF. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+6.46%
ELVAF - REPL
60%
Loosely correlated
N/A
SNDX - REPL
49%
Loosely correlated
+2.60%
IDYA - REPL
46%
Loosely correlated
+2.99%
XNCR - REPL
44%
Loosely correlated
+5.81%
KYMR - REPL
43%
Loosely correlated
-0.08%
More

SRPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with ALZN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then ALZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRPT
1D Price
Change %
SRPT100%
+9.69%
ALZN - SRPT
49%
Loosely correlated
-2.69%
AXON - SRPT
43%
Loosely correlated
+1.52%
REPL - SRPT
42%
Loosely correlated
+6.46%
TECX - SRPT
42%
Loosely correlated
+1.77%
ARWR - SRPT
41%
Loosely correlated
+2.13%
More